Literature DB >> 16078104

Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.

Sean D McAllister1, Calvin Chan, Ryan J Taft, Tri Luu, Mary E Abood, Dan H Moore, Ken Aldape, Garret Yount.   

Abstract

Normal tissue toxicity limits the efficacy of current treatment modalities for glioblastoma multiforme (GBM). We evaluated the influence of cannabinoids on cell proliferation, death, and morphology of human GBM cell lines and in primary human glial cultures, the normal cells from which GBM tumors arise. The influence of a plant derived cannabinoid agonist, Delta(9)-tetrahydrocannabinol Delta(9)-THC), and a potent synthetic cannabinoid agonist, WIN 55,212-2, were compared using time lapse microscopy. We discovered that Delta(9)-THC decreases cell proliferation and increases cell death of human GBM cells more rapidly than WIN 55,212-2. Delta(9)-THC was also more potent at inhibiting the proliferation of GBM cells compared to WIN 55,212-2. The effects of Delta(9)-THC and WIN 55,212-2 on the GBM cells were partially the result of cannabinoid receptor activation. The same concentration of Delta(9)-THC that significantly inhibits proliferation and increases death of human GBM cells has no significant impact on human primary glial cultures. Evidence of selective efficacy with WIN 55,212-2 was also observed but the selectivity was less profound, and the synthetic agonist produced a greater disruption of normal cell morphology compared to Delta(9)-THC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078104     DOI: 10.1007/s11060-004-5950-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  31 in total

Review 1.  Targeting the endocannabinoid system in cancer therapy: a call for further research.

Authors:  Maurizio Bifulco; Vincenzo Di Marzo
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

2.  Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.

Authors:  I Galve-Roperh; C Sánchez; M L Cortés; T Gómez del Pulgar; M Izquierdo; M Guzmán
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

3.  Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.

Authors:  G Griffin; P J Atkinson; V M Showalter; B R Martin; M E Abood
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

Review 4.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

5.  delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1.

Authors:  L Velasco; L Ruiz; M G Sánchez; I Díaz-Laviada
Journal:  Eur J Biochem       Date:  2001-02

6.  Using computerized video time lapse for quantifying cell death of X-irradiated rat embryo cells transfected with c-myc or c-Ha-ras.

Authors:  H B Forrester; C A Vidair; N Albright; C C Ling; W C Dewey
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

7.  Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity.

Authors:  C S Breivogel; D E Selley; S R Childers
Journal:  J Biol Chem       Date:  1998-07-03       Impact factor: 5.157

8.  Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor.

Authors:  Stefan Hart; Oliver M Fischer; Axel Ullrich
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

9.  An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.

Authors:  Sean D McAllister; Gulrukh Rizvi; Sharon Anavi-Goffer; Dow P Hurst; Judy Barnett-Norris; Diane L Lynch; Patricia H Reggio; Mary E Abood
Journal:  J Med Chem       Date:  2003-11-20       Impact factor: 7.446

10.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

View more
  19 in total

1.  Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.

Authors:  Sara Jane Ward; Sean D McAllister; Rumi Kawamura; Ryuchi Murase; Harshini Neelakantan; Ellen A Walker
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  Cannabinoids, endocannabinoids, and cancer.

Authors:  Daniel J Hermanson; Lawrence J Marnett
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 3.  Cannabinoids and cancer: pros and cons of an antitumour strategy.

Authors:  Maurizio Bifulco; Chiara Laezza; Simona Pisanti; Patrizia Gazzerro
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.

Authors:  Sean D McAllister; Ryuichi Murase; Rigel T Christian; Darryl Lau; Anne J Zielinski; Juanita Allison; Carolina Almanza; Arash Pakdel; Jasmine Lee; Chandani Limbad; Yong Liu; Robert J Debs; Dan H Moore; Pierre-Yves Desprez
Journal:  Breast Cancer Res Treat       Date:  2010-09-22       Impact factor: 4.872

6.  CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.

Authors:  M Rajesh; P Mukhopadhyay; G Haskó; J W Huffman; K Mackie; P Pacher
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

7.  Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Authors:  Jahan P Marcu; Rigel T Christian; Darryl Lau; Anne J Zielinski; Maxx P Horowitz; Jasmine Lee; Arash Pakdel; Juanita Allison; Chandani Limbad; Dan H Moore; Garret L Yount; Pierre-Yves Desprez; Sean D McAllister
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

Review 8.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 9.  Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue.

Authors:  Eiron Cudaback; Nephi Stella
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

10.  Expression of cannabinoid receptors and neurotrophins in human gliomas.

Authors:  C Calatozzolo; A Salmaggi; B Pollo; F L Sciacca; M Lorenzetti; A Franzini; A Boiardi; G Broggi; C Marras
Journal:  Neurol Sci       Date:  2008-01-04       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.